Immunotherapy in myeloma: Why, when and how?

por van de Donk, Niels W.C.J.
Publicado 2018

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma

por Krejcik, Jakub, van de Donk, Niels W.C.J.
Publicado 2018

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions

por O'Neill, Chloe, van de Donk, Niels W. C. J.
Publicado 2023

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

por van de Donk, Niels W.C.J., Usmani, Saad Z.
Publicado 2018

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches

por van de Donk, Niels W. C. J., Kastritis, Efstathios, Gay, Francesca
Publicado 2020

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

por Radocha, Jakub, van de Donk, Niels W. C. J., Weisel, Katja
Publicado 2021

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

por Plesner, Torben, van de Donk, Niels W. C. J., Richardson, Paul G.
Publicado 2020

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

por Nijhof, Inger S., van de Donk, Niels W. C. J., Zweegman, Sonja, Lokhorst, Henk M.
Publicado 2017

Targeted Therapy With Immunoconjugates for Multiple Myeloma

por Bruins, Wassilis S. C., Zweegman, Sonja, Mutis, Tuna, van de Donk, Niels W. C. J.
Publicado 2020

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment

por van der Schans, Jort J., van de Donk, Niels W. C. J., Mutis, Tuna
Publicado 2020

Immunotherapy in myeloma: how far have we come?

por Franssen, Laurens E., Mutis, Tuna, Lokhorst, Henk M., van de Donk, Niels W. C. J.
Publicado 2019

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment

por Frerichs, Kristine A., Bosman, Patricia W.C., Nijhof, Inger S., Zweegman, Sonja, van de Donk, Niels W.C.J.
Publicado 2019

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

por Franssen, Laurens E., Stege, Claudia A. M., Zweegman, Sonja, van de Donk, Niels W. C. J., Nijhof, Inger S.
Publicado 2020

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018

por Brink, Mirian, Visser, Otto, Zweegman, Sonja, Sonneveld, Pieter, Broyl, Annemiek, van de Donk, Niels W.C.J., Dinmohamed, Avinash G.
Publicado 2021

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA

por van de Donk, Niels W.C.J., O’Neill, Chloe, de Ruijter, Maaike E.M., Verkleij, Christie P.M., Zweegman, Sonja
Publicado 2023

Primary cardiac lymphoma with central nervous system relapse

por van Rooijen, Cleo R., Scholtens, Asbjorn M., de Jong, C. Niels, Saraber, Colette E., van de Donk, Niels W. C. J.
Publicado 2017

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

por Drent, Esther, Poels, Renée, Mulders, Manon J., van de Donk, Niels W. C. J., Themeli, Maria, Lokhorst, Henk M., Mutis, Tuna
Publicado 2018

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

por Frerichs, Kristine A., Verkleij, Christie P.M., Bosman, Patricia W.C., Zweegman, Sonja, Otten, Henny, van de Donk, Niels W.C.J.
Publicado 2019

Waldenström macroglobulinemia presenting as nephrotic syndrome: Renal heavy and light chain amyloidosis

por Kwakernaak, Arjan J., Bernelot Moens, Sophie J., Hilhorst, Marc L., Florquin, Sandrine, van de Donk, Niels W.C.J., Vos, Josephine M.I.
Publicado 2022

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma

por Hosny, Mashhour, Verkleij, Christie P. M., van der Schans, Jort, Frerichs, Kristine A., Mutis, Tuna, Zweegman, Sonja, van de Donk, Niels W. C. J.
Publicado 2021